Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Use of Topical Rho Kinase Inhibitors in the Treatment of Fuchs Dystrophy After Descemet Stripping Only

Macsai, Marian S., MD; Shiloach, Mira, MSc, CCRP

doi: 10.1097/ICO.0000000000001883
Clinical Science
Buy
SDC

Purpose: Fuchs corneal dystrophy (FD) is a common cause of endothelial keratoplasty. Recently, a series of FD cases treated with Descemet stripping only (DSO) demonstrated recovery of the central endothelium without transplantation of donor cells. Ripasudil, a rho kinase inhibitor, has been shown to promote corneal endothelial wound healing in animal models. This study prospectively evaluated the use of ripasudil in patients undergoing DSO for FD.

Methods: Enrolled patients underwent DSO with or without cataract surgery, performed by 1 surgeon. On the first postoperative day, patients were assigned to topical ripasudil 0.4% (Glanatec) 4 times a day for 2 months or no ripasudil and followed up monthly for the first 6 months and then at 9 and 12 months after surgery. Endothelial cell density (ECD) and pachymetry were evaluated at each postoperative visit.

Results: Eighteen patients were enrolled, including 8 women and 1 man in each group. Overall, patients who underwent DSO with ripasudil recovered vision more quickly (4.6 vs. 6.5 weeks, P < 0.01). In addition, the ripasudil group had a statistically significantly higher average ECD at 3, 6, and 12 months. The patients in the DSO observation group had a 10% decrease in peripheral ECD when comparing counts before surgery with counts 12 months after surgery (P < 0.05). In the DSO ripasudil group, there was no significant difference between peripheral ECD at preoperative baseline versus 12 months after surgery.

Conclusions: DSO with topical rho kinase inhibitors may be an alternative treatment for patients with FD and a peripheral ECD greater than 1000 cells/mm2.

Division of Ophthalmology, NorthShore University HealthSystem, Glenview, IL.

Correspondence: Marian S. Macsai, MD, NorthShore University HealthSystem, 2150 Pfingsten Rd, Suite 220, Glenview, IL 60026 (e-mail: mmacsai@northshore.org).

The authors have no funding or conflicts of interest to disclose.

Received August 14, 2018

Received in revised form December 15, 2018

Accepted December 17, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.